Published online May 7, 2016. doi: 10.3748/wjg.v22.i17.4307
Peer-review started: January 28, 2016
First decision: March 7, 2016
Revised: March 14, 2016
Accepted: March 30, 2016
Article in press: March 30, 2016
Published online: May 7, 2016
Processing time: 93 Days and 19.2 Hours
Gastric cancer has an important place in the worldwide incidence of cancer and cancer-related deaths. It can metastasize to the lymph nodes in the early stages, and lymph node metastasis is an important prognostic factor. Surgery is a very important part of gastric cancer treatment. A D2 lymphadenectomy is the standard surgical treatment for cT1N+ and T2-T4 cancers, which are potentially curable. Recently, the TNM classification system was reorganized, and the margins for gastrectomy and lymphadenectomy were revised. Endoscopic, laparoscopic and robotic treatments of gastric cancer have progressed rapidly with development of surgical instruments and techniques, especially in Eastern countries. Different endoscopic resection techniques have been identified, and these can be divided into two main categories: endoscopic mucosal resection and endoscopic submucosal dissection. Minimally invasive surgery has been reported to be safe and effective for early gastric cancer, and it can be successfully applied to advanced gastric cancer with increasing experience. Cytoreductive surgery and hyperthermıc intraperıtoneal chemotherapy were developed as a combined treatment modality from the results of experimental and clinical studies. Also, hyperthermia increases the antitumor activity and penetration of chemotherapeutics. Trastuzumab which is a monoclonal antibody interacts with human epidermal growth factor (HER) 2 and is related to gastric carcinoma. The anti-tumor mechanism of trastuzumab is not clearly known, but mechanisms such as interruption of the HER2-mediated cell signaling pathways and cell cycle progression have been reported previously. H. pylori is involved in 90% of all gastric malignancies and Japanese guidelines strongly recommend that all H. pylori infections should be eradicated regardless of the associated disease. In this review, we present innovations discussed in recent studies.
Core tip: Gastric cancers are distinguished from other cancers by their high mortality and morbidity. Many studies have been conducted to improve the quality of life and extend the survival rates of patients, and some of these studies are ongoing. Although promising developments have been made in recent years, the obtained results have limited reliability and benefits. We believe that significant improvements in the treatment of gastric cancer will be developed according to the long-term results of ongoing randomized clinical trials.